Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Diese Artikel erschien zuerst auf GuruFocus. Betriebliche Umsätze betrugen EUR152,5 Millionen, ein Rückgang um 1,5% im Vergleich zum ersten Quartal 2025. Bruttogewinn betrug EUR95 Millionen, ein Anstieg von 5%, mit einer Verbesserung der Bruttomarge um 3,8 Prozentpunkte auf 62,3%. Die Vertragsfertigungsgeschäft brachte einen Umsatzzuwachs von 5% auf EUR37,4 Millionen. Heparin-Division-Umsätze sanken um 12% aufgrund niedrigerer Bemiparin-Verkäufe. Okedi-Umsätze betrugen EUR17,2 Millionen, ein Anstieg um 37% im Vergleich zum Vorjahr. SG&A-Ausgaben stiegen um 18% auf EUR63,6 Millionen. R&D-Ausgaben erhöhten sich um 79% auf EUR11,2 Millionen. EBITDA betrug EUR20,3 Millionen mit einer Marge von 13,3%. Nettoertrag: EUR9,4 Millionen. Betriebliche Cash-Flow: EUR13 Millionen. Freier Cash-Flow: EUR5,6 Millionen. Netto-Schuldenposition: EUR14,9 Millionen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

This article first appeared on GuruFocus.

Total Revenue: EUR 756.1 million, a 1% decrease compared with 2024. Operating Revenue: EUR 743.5 million, a 2% decrease versus 2024. Gross Margin: 66.5%, an improvement of 3.9 percentage points compared to 2024. EBITDA: EUR 216.2 million, a 4% increase compared to 2024. EBITDA Margin: 29.1%, an increase of 1.9 percentage points. Net Profit: EUR 140.4 million, a 3% increase in 2025. Specialty Pharmaceutical Business Revenue: EUR 473.9 million, up 11%. Heparin Division Sales: EUR 414.1 million, increased by 11%. Enoxaparin Sales: EUR 157.7 million, a 9% increase. Bemiparin Sales: Increased 4% in 2025. CMO Business Sales: EUR 269.5 million, a 20% decline. R&D Expenses: EUR 37.8 million, a 47% increase. SG&A Expenses: EUR 240.7 million, a 2% decrease. CapEx: EUR 67 million, with EUR 46.2 million for investment CapEx. Free Cash Flow: EUR 120 million, 57% higher than in 2024. Total Debt: EUR 121.8 million as of December 31, 2025. Net Debt: EUR 21.9 million. Dividend Proposal: Over EUR 49 million, equivalent to EUR 0.9594 per share.

Warning! GuruFocus has detected 11 Warning Sign with SEGXF. Is STU:41L fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 25, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Laboratorios Farmaceuticos Rovi SA (STU:41L) reported a 4% increase in EBITDA, with the EBITDA margin expanding by 1.9 percentage points to 29.1% in 2025. The specialty pharmaceutical business saw an 11% increase in sales, driven by strong performance in the heparin division and products like OKEDI and Neparvis. The company announced a collaboration with Roche for the manufacture of a new medicine, reflecting strong momentum in new business and partnership expansion. Rovi acquired a manufacturing site in Phoenix, Arizona, enhancing its US-based manufacturing capabilities and adding high-potent cytotoxic capacities. The company advanced in artificial intelligence by acquiring a majority stake in Celis IA Technology, aiming to transform diagnostics in pathological anatomy.

Negative Points

Total revenue in 2025 decreased by 1% compared to 2024, with operating revenue falling by 2%, mainly due to the performance of the CDMO business. Sales in the CMO business declined by 20%, primarily due to minimal revenue recognition related to Moderna vaccine production. The company expects a decline in heparin sales in 2026 due to aggressive pricing strategies from Chinese competitors and strong stock levels from partners. R&D expenses increased by 47% in 2025, driven by the completion of Phase 1 clinical trials and preparation for further development, impacting overall costs. The company anticipates significant R&D expenditure in 2026, potentially exceeding previous expectations, due to the start of patient recruitment for clinical trials.

Story Continues

Q & A Highlights

Q: Could you share any indication on your clients intentions regarding the 100 million-unit capacity expected to be operational this year? Specifically, the agreement is expected to contribute between EUR80 million and EUR180 million. Do you have any sense of whether the client is likely to utilize this capacity fully or whether it is intended more as a backup option? Has there been any change to the timeline for commissioning the line, or does September still look like the official target date? A: We cannot comment much on specific contracts for confidentiality reasons, but we are carrying out a technology-transfer process that will require regulatory approvals this year, and commercial production is expected to commence most likely in the second part of the year. Expectations remain the same, with 2027 expected to be the first full year of recurrent manufacturing, impacting our accounts by 20% to 45% over 2023 sales. (Javier Lopez-Belmonte Encina, CFO)

Q: Could you comment on the latest trends regarding heparin raw material cost evolution and to what extent this could offset potential price pressures in 2026? A: We are seeing aggressive pricing strategies from Chinese players. Our focus is on executing plans to improve cost efficiency and deliver higher gross margins. The kickoff of operations at our new manufacturing plant with full vertical integration of our supply chain will be critical. We believe we have positive trends ahead once we can in-house source crude heparin manufacturing. (Juan Lopez-Belmonte Encina, CEO)

Q: What is your view on SG&A evolution in 2026? A: We expect to expand our operations, which will require some SG&A expansion, but hopefully in a very moderate way. We reduced SG&A in 2025, which is difficult to replicate, but we aim to be strict on cost expansion. (Javier Lopez-Belmonte Encina, CFO)

Q: Could you talk about reaching Phase three for quarterly Risperidone and Letrozole in 2026? And what do you think the Phase three would last? A: Our target is to start recruitment in the second quarter of this year for the Letrozole quarterly injection. The clinical trial is expected to be finalized by 2030 or 2031. This will be a major milestone for the company, showing our long-term perspective. (Juan Lopez-Belmonte Encina, CEO)

Q: After the excellent year in heparins, what are your expectations for 2026? A: We expect a decline in sales due to strong international performance in late 2025 and aggressive pricing strategies from Chinese competitors. We are investing heavily to improve cost efficiency and remain excited about long-term opportunities. (Juan Lopez-Belmonte Encina, CEO)

Q: After the lower R&D in 2025 versus expectations, could you update if in 2026 it should go above the range of EUR40 million to EUR60 million commented? A: R&D spending is linked to the evolution of clinical trials, and we expect 2026 to be intensive in R&D expenditure. We still expect to spend around EUR300 million over the five-year R&D program from 2026 to 2030. (Javier Lopez-Belmonte Encina, CFO)

Q: Can you provide some detail on Proviss prospects and the timing of the loss of exclusivity? A: Provis will lose its patent around November this year. It has been a tremendous success, demonstrating our strong commercial capabilities in Spain. (Juan Lopez-Belmonte Encina, CEO)

Q: What is the likelihood of signing an additional CDMO contract in 2026? A: We are excited about the business momentum and are signing contracts in a very recurrent way. The acquisition of Rovi Phoenix will likely speed up closing agreements in the coming months. (Javier Lopez-Belmonte Encina, CFO)

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

As the pan-European STOXX Europe 600 Index reaches new intraday highs, optimism about the eurozone economy is helping to counteract recent market volatility. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities that may offer potential value as the broader market sentiment remains buoyant.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

Name Current Price Fair Value (Est) Discount (Est) Streamwide (ENXTPA:ALSTW) €73.20 €144.32 49.3% Outokumpu Oyj (HLSE:OUT1V) €5.18 €10.19 49.1% Nokian Panimo Oyj (HLSE:BEER) €2.47 €4.88 49.4% Grieg Seafood (OB:GSF) NOK72.90 NOK143.53 49.2% Exel Composites Oyj (HLSE:EXL1V) €0.536 €1.06 49.4% Doxee (BIT:DOX) €4.33 €8.60 49.6% Cambi (OB:CAMBI) NOK17.60 NOK34.79 49.4% B&S Group (ENXTAM:BSGR) €5.85 €11.66 49.8% Bike24 Holding (XTRA:BIKE) €3.04 €6.03 49.6% Asker Healthcare Group (OM:ASKER) SEK70.65 SEK139.12 49.2%

Click here to see the full list of 208 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

Laboratorios Farmaceuticos Rovi

Overview: Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that manufactures, sells, and markets its products in Spain, the European Union, OECD countries, and internationally with a market cap of €3.85 billion.

Operations: Laboratorios Farmaceuticos Rovi generates its revenue through the manufacture, sale, and marketing of pharmaceutical products across Spain, the European Union, OECD countries, and other international markets.

Estimated Discount To Fair Value: 34.2%

Laboratorios Farmaceuticos Rovi is trading at €75.2, significantly below its estimated future cash flow value of €114.25, presenting a potential undervaluation opportunity based on cash flows. The company’s earnings are projected to grow 19.1% annually, outpacing the Spanish market's growth rate of 7.1%. Despite revenue growth being moderate at 10.6% per year, it still surpasses the Spanish market average of 5.6%, reinforcing its investment appeal in terms of cash flow valuation.

The growth report we've compiled suggests that Laboratorios Farmaceuticos Rovi's future prospects could be on the up. Delve into the full analysis health report here for a deeper understanding of Laboratorios Farmaceuticos Rovi.BME:ROVI Discounted Cash Flow as at Feb 2026

Sdiptech

Overview: Sdiptech AB (publ) offers technical services for infrastructures across various countries including Sweden, the UK, Germany, and others, with a market cap of SEK7.18 billion.

Operations: The company's revenue segments total SEK5.21 billion, derived from providing technical infrastructure services across multiple countries including Sweden, the UK, Germany, and others.

Story Continues

Estimated Discount To Fair Value: 46%

Sdiptech AB is trading at SEK189, below its estimated future cash flow value of SEK349.91, highlighting a potential undervaluation. The company reported strong quarterly earnings with net income rising to SEK225 million from SEK107 million the previous year. Despite high debt levels and moderate revenue growth forecasts of 5.4% annually, Sdiptech's strategic focus on M&A could enhance cash flow generation, supported by their robust internal capabilities and recent executive appointments in energy and electrification sectors.

According our earnings growth report, there's an indication that Sdiptech might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of Sdiptech.OM:SDIP B Discounted Cash Flow as at Feb 2026

Partners Group Holding

Overview: Partners Group Holding AG is a private equity firm that focuses on direct, secondary, and primary investments in private equity, real estate, infrastructure, and debt with a market cap of CHF25.58 billion.

Operations: The company's revenue segments include CHF1.43 billion from Private Equity, CHF471.40 million from Infrastructure, CHF215.80 million from Real Estate, and CHF207.40 million from Private Credit.

Estimated Discount To Fair Value: 27.7%

Partners Group Holding is trading at CHF986, significantly below its estimated future cash flow value of CHF1363.69, suggesting potential undervaluation. Despite high debt levels and a dividend yield of 4.26% not well covered by earnings or free cash flows, the company's earnings are forecast to grow at 10.16% annually, outpacing the Swiss market slightly. Recent strategic initiatives include launching multi-alternative SMA solutions with BlackRock and acquiring The Hoxton Poblenou hotel in Barcelona to enhance asset diversification and operational efficiency.

In light of our recent growth report, it seems possible that Partners Group Holding's financial performance will exceed current levels. Get an in-depth perspective on Partners Group Holding's balance sheet by reading our health report here.SWX:PGHN Discounted Cash Flow as at Feb 2026

Key Takeaways

Unlock our comprehensive list of 208 Undervalued European Stocks Based On Cash Flows by clicking here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:ROVI OM:SDIP B and SWX:PGHN.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here's a 600-word summary of the text, followed by a German translation:

Summary (600 words)

This article, published by Simply Wall St, highlights a list of 205 undervalued European stocks identified through a cash flow analysis. The core premise is that market inefficiencies can create opportunities for investors to buy stocks trading below their intrinsic value. The article focuses on several key stocks, illustrating the methodology and potential investment opportunities.

Key Findings & Methodology:

The analysis utilizes a Discounted Cash Flow (DCF) valuation method. This involves estimating a company's future cash flows and discounting them back to their present value to arrive at a “fair value” estimate. The difference between the current market price and this estimated fair value represents the “discount,” indicating potential undervaluation. The article identifies several European companies with significant discounts, suggesting they may be mispriced by the market.

Featured Stocks & Analysis:

• Laboratorios Farmaceuticos Rovi (BME:ROVI): A Spanish pharmaceutical company trading at a significant 31.1% discount to its estimated fair value. Despite recent revenue and profit declines, the company is projected to experience robust annual growth (19.2%) surpassing the Spanish market average, indicating future potential.
• STMicroelectronics (ENXTPA:STMPA): A semiconductor manufacturer with a 19.2% discount. While facing lower profit margins, strategic collaborations (SpaceX) and financing agreements provide support, although revenue growth projections are lower than broader market expectations.
• Sonova Holding (SWX:SOON): A hearing care company with a substantial 49.9% discount. Despite a recent dip in sales, strategic reorganization and innovative products suggest continued growth potential and a strong future.

Overall Market Context:

The analysis is conducted within an environment of optimism regarding the European economy and favorable interest rates. This supportive backdrop encourages investors to seek undervalued assets, particularly those with strong growth prospects.

Investment Recommendations & Further Exploration:

The article encourages readers to explore the full list of 205 stocks, presented through a screener. It highlights the importance of considering individual company fundamentals and acknowledging the limitations of relying solely on analyst forecasts. The article recommends utilizing Simply Wall St’s platform for portfolio monitoring and further research, providing a comprehensive overview of company financials. It suggests focusing on companies with strong growth potential, dividend income opportunities, and diversification strategies to mitigate risk. The article emphasizes a long-term, fundamentally-driven investment approach.

Disclaimer: The article includes a clear disclaimer emphasizing that its analysis is based on historical data and analyst forecasts, and does not constitute financial advice. It doesn’t take into account individual investor objectives or financial situations. Simply Wall St has no position in any of the stocks discussed.

German Translation (approx. 600 words)

Zusammenfassung (600 Wörter)

Dieser Artikel, veröffentlicht von Simply Wall St, beleuchtet eine Liste von 205 unterbewerteten europäischen Aktien, die mithilfe einer Analyse der Cashflows identifiziert wurden. Das Kernthema ist, dass Marktineffizienzen Möglichkeiten für Investoren schaffen, Aktien zu kaufen, die unter ihrem inneren Wert gehandelt werden. Der Artikel konzentriert sich auf mehrere Schlüsselaktien, um die Methodik und die potenziellen Anlagechancen zu veranschaulichen.

Schlüsselergebnisse und Methodik:

Die Analyse verwendet eine Discounted Cash Flow (DCF)-Bewertungsmethode. Dabei werden die zukünftigen Cashflows eines Unternehmens geschätzt und auf ihren heutigen Wert abgezinst, um einen geschätzten “Fair Value” zu ermitteln. Die Differenz zwischen dem aktuellen Marktpreis und diesem geschätzten Fair Value stellt den “Discount” dar, der potenzielle Unterbewertung anzeigt. Der Artikel identifiziert mehrere europäische Unternehmen mit erheblichen Rabatten, was darauf hindeutet, dass sie vom Markt falsch bewertet werden könnten.

Hervorgehobene Aktien und Analyse:

• Laboratorios Farmacéuticos Rovi (BME:ROVI): Ein spanisches Pharmaunternehmen, das mit einem erheblichen Rabatt von 31,1 % auf seinen geschätzten Fair Value gehandelt wird. Trotz jüngster Umsatzeinbußen und Gewinnrückgänge wird das Unternehmen robuste jährliche Wachstumsprognosen (19,2 %) erzielen, die höher sind als der durchschnittliche Wachstumspfad der spanischen Märkte, was zukünftiges Potenzial andeutet.
• STMicroelectronics (ENXTPA:STMPA): Ein Halbleiterhersteller mit einem Rabatt von 19,2 %. Obwohl die Gewinnmargen niedriger sind, bieten strategische Kooperationen (SpaceX) und Finanzierungsvereinbarungen Unterstützung, obwohl die Umsatzwachstumsprognosen niedriger sind als die breiteren Markt erwartungen.
• Sonova Holding (SWX:SOON): Ein Hörsicherheitsunternehmen mit einem erheblichen Rabatt von 49,9 %. Trotz eines jüngsten Rückgangs der Verkäufe und des Gewinns folgt die strategische Neuausrichtung und die innovativen Produkte aufschlussreiche Wachstumsaussichten und betriebliche Effizienz.

Gesamtmarktkontext:

Die Analyse wird in einer Umgebung von Optimismus hinsichtlich der europäischen Wirtschaft und günstigen Zinssätzen durchgeführt. Dieser unterstützende Hintergrund ermutigt Investoren, nach unterbewerteten Vermögenswerten zu suchen, insbesondere solchen mit soliden Wachstumsaussichten.

Anlageempfehlungen und weitere Erkundung:

Der Artikel ermutigt die Leser, die vollständige Liste von 205 Aktien, die über einen Screener präsentiert wird, zu erkunden. Es betont die Bedeutung der Berücksichtigung der individuellen Unternehmensgrundlagen und der Anerkennung der Grenzen des reinen Verlassens von Analystenprognosen. Der Artikel empfiehlt die Nutzung der Simply Wall St-Plattform zur Portfolioüberwachung und weiterführender Forschung und bietet eine umfassende Übersicht über die Unternehmensfinanzen. Es wird empfohlen, sich auf Unternehmen mit starkem Wachstumspotenzial, Einkommensstrommöglichkeiten und Diversifizierungsstrategien zu konzentrieren, um Risiken zu mindern. Der Artikel betont einen langfristigen, fundamentalen Anlageansatz.

Haftungsausschluss: Der Artikel enthält einen klaren Haftungsausschluss, der betont, dass seine Analyse auf historischen Daten und Analystenprognosen basiert und keine Finanzberatung darstellt. Es berücksichtigt nicht die individuellen Anlageziele oder die finanziellen Situationen der Anleger. Simply Wall St hält sich nicht an Aktien, die in dem Artikel erwähnt werden.

Would you like me to adjust the summary or translation in any way?

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a summary of the text, followed by the German translation:

Summary (approx. 600 words)

As of December 2025, the European stock market exhibits mixed performance. While indices like Germany’s DAX are showing gains, others, such as France's CAC 40, are experiencing declines. This environment is driving investors to seek out stocks trading below their perceived fair value, particularly those with strong cash flow potential. The core strategy is identifying undervalued companies – those where the market price is lower than what a thorough analysis suggests the company is truly worth.

The article highlights ten European stocks identified through a “Discounted Cash Flow” (DCF) analysis, a valuation method used to estimate the intrinsic value of a company based on its expected future cash flows. The analysis focuses on these companies as potential undervalued investments.

Here's a breakdown of the key findings:

• Laboratorios Farmaceuticos Rovi (BME:ROVI): This Spanish pharmaceutical company is trading at approximately 38% below its estimated fair value. Despite recent sales and income decreases, the company is projected to experience significant earnings growth of 21.3% annually over the next three years, surpassing the Spanish market’s growth rate.

• Apotea (OM:APOTEA): This Swedish online pharmacy is priced around 25% below its estimated value. Revenue is up year-over-year, and the company anticipates 17.7% annual growth, exceeding the Swedish market average of 13.5%.

• JOST Werke (XTRA:JST): This German manufacturer of safety systems for commercial vehicles is undervalued by roughly 18%. Despite debt and volatile dividends, JOST Werke’s earnings are forecasted to grow by 47.1% annually.

The article emphasizes the use of DCF analysis as a tool to identify companies potentially overlooked by the market. It stresses the importance of future cash flow projections when evaluating a company's worth. The article also points out the potential for growth within the companies highlighted.

Beyond these ten stocks, the article encourages investors to explore the broader “Undervalued European Stocks Based On Cash Flows” screener, which contains 192 companies. It suggests diversifying investments by looking at high-performing small-cap companies, dividend-paying stocks, and companies with strong growth prospects.

The article concludes by highlighting Simply Wall St’s tools for investors, including portfolio tracking and analysis. Importantly, it clearly states that this is a general, data-driven analysis, not financial advice, and that it’s based on historical data and analyst forecasts, acknowledging that it doesn't account for the latest company announcements.

German Translation (approx. 600 words)

Zusammenfassung (ca. 600 Wörter)

Stand Dezember 2025 zeigt die europäische Aktienmärkte gemischte Ergebnisse. Während Indizes wie der DAX in Deutschland Gewinne verzeichnen, erleben andere, wie der CAC 40 in Frankreich, Rückgänge. Diese Situation treibt Investoren dazu an, Aktien zu suchen, die unter ihrem wahrgenommenen fairen Wert gehandelt werden, insbesondere solche mit einem starken Potenzial für Cashflow. Die Kernstrategie besteht darin, unterbewertete Unternehmen zu identifizieren – solche, bei denen der Marktpreis niedriger ist als was eine gründliche Analyse vorschlägt, dass das Unternehmen tatsächlich wert ist.

Der Artikel beleuchtet zehn europäische Aktien, die durch eine „Discounted Cash Flow“- (DCF-) Analyse identifiziert wurden, eine Bewertungsmethode, die zur Schätzung des intrinsischen Werts eines Unternehmens auf der Grundlage seiner erwarteten zukünftigen Cashflows verwendet wird. Es wird betont, dass die Analyse auf diesen Unternehmen als potenzielle unterbewertete Investitionen basiert.

Hier ist eine Zusammenfassung der wichtigsten Ergebnisse:

• Laboratorios Farmacéuticos Rovi (BME:ROVI): Dieses spanische Pharmaunternehmen wird zu etwa 38 % unter seinem geschätzten fairen Wert gehandelt. Trotz kürzlicher Umsatzeinbußen und Einkommensrückgängen wird erwartet, dass das Unternehmen aufgrund von Erwartungen für ein jährliches Wachstum von 21,3 % über die nächsten drei Jahre, das höher ist als die spanische Marktgrowthrate, erhebliche Gewinne erzielt.

• Apotea (OM:APOTEA): Diese schwedische Online-Apotheke wird zu etwa 25 % unter ihrem geschätzten Wert gehandelt. Der Umsatz ist im Jahresvergleich gestiegen, und das Unternehmen erwartet ein jährliches Wachstum von 17,7 %, das höher ist als der durchschnittliche Wachstumstrend in Schweden von 13,5 %.

• JOST Werke (XTRA:JST): Dieser deutsche Hersteller von Sicherheitssystemen für den Güterverkehr wird zu etwa 18 % unter seinem geschätzten Wert gehandelt. Trotz Schulden und volatilen Dividenden wird JOST Werke aufgrund von Erwartungen für ein jährliches Wachstum von 47,1 % prognostiziert.

Der Artikel betont die Verwendung der DCF-Analyse als Werkzeug zur Identifizierung von Unternehmen, die vom Markt übersehen werden. Es wird die Bedeutung zukünftiger Cashflow-Prognosen bei der Bewertung eines Unternehmens hervorgehoben. Der Artikel weist auch auf das Wachstumspotenzial innerhalb der hervorgehobenen Unternehmen hin.

Neben diesen zehn Aktien ermutigt der Artikel Investoren, die breitere „Undervalued European Stocks Based On Cash Flows“-Suche zu erkunden, die 192 Unternehmen enthält. Es wird empfohlen, Investitionen zu diversifizieren, indem man sich auf kleine Caps Unternehmen, dividendenzahlende Aktien und Unternehmen mit großem Wachstumspotenzial konzentriert.

Der Artikel schließt mit der Hervorhebung der Tools von Simply Wall St für Investoren, einschließlich Portfolioverfolgung und Analyse. Es wird deutlich betont, dass dies eine allgemeine, datengesteuerte Analyse ist, die nicht als Finanzberatung gedacht ist und auf historischen Daten und Analystenprognosen basiert, wobei berücksichtigt wird, dass sie die neuesten Unternehmensmitteilungen nicht berücksichtigt.

Ich hoffe diese Zusammenfassung und Übersetzung sind hilfreich!

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

In November 2025, global markets are grappling with a complex mix of factors, including record-low U.S. consumer sentiment and a prolonged government shutdown impacting investor confidence. Amidst these challenges, the search for value becomes paramount as investors look for stocks that may be priced below their estimated worth, offering potential opportunities in an uncertain economic environment.

Top 10 Undervalued Stocks Based On Cash Flows

Name Current Price Fair Value (Est) Discount (Est) Roche Bobois (ENXTPA:RBO) €34.80 €69.24 49.7% PharmaEssentia (TWSE:6446) NT$482.50 NT$963.42 49.9% Nokian Panimo Oyj (HLSE:BEER) €2.45 €4.88 49.8% Nippon Thompson (TSE:6480) ¥708.00 ¥1412.69 49.9% Nichicon (TSE:6996) ¥1296.00 ¥2584.67 49.9% Mobvista (SEHK:1860) HK$18.86 HK$37.71 50% Food Empire Holdings (SGX:F03) SGD2.57 SGD5.06 49.2% E-Globe (BIT:EGB) €0.645 €1.29 50% eDreams ODIGEO (BME:EDR) €7.21 €14.35 49.7% Corporativo Fragua. de (BMV:FRAGUA B) MX$540.00 MX$1065.06 49.3%

Click here to see the full list of 499 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Laboratorios Farmaceuticos Rovi

Overview: Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that manufactures, sells, and markets its products in Spain, the European Union, OECD countries, and internationally with a market cap of €3.01 billion.

Operations: Laboratorios Farmaceuticos Rovi, S.A. generates revenue through the production and distribution of pharmaceutical products across Spain, the European Union, OECD countries, and other international markets.

Estimated Discount To Fair Value: 41.3%

Laboratorios Farmaceuticos Rovi is trading at €58.85, significantly below its estimated fair value of €100.24, indicating potential undervaluation based on cash flows. Despite a recent dip in sales and net income for the nine months ending September 2025, earnings are forecast to grow by 20.54% annually, outpacing the Spanish market's growth rate. The company's acquisition of a manufacturing site in Phoenix could bolster future revenue streams and operational capacity.

According our earnings growth report, there's an indication that Laboratorios Farmaceuticos Rovi might be ready to expand. Unlock comprehensive insights into our analysis of Laboratorios Farmaceuticos Rovi stock in this financial health report.BME:ROVI Discounted Cash Flow as at Nov 2025

Suning.com

Overview: Suning.com Co., Ltd. operates as a retail business in China with a market cap of CN¥16.48 billion.

Operations: Suning.com Co., Ltd. generates its revenue primarily through its retail operations in China.

Story Continues

Estimated Discount To Fair Value: 44.1%

Suning.com is trading at CN¥1.82, significantly below its estimated fair value of CN¥3.26, highlighting potential undervaluation based on cash flows. The company's earnings are forecast to grow substantially at 63% annually over the next three years, surpassing the broader Chinese market growth rate. However, recent financial results show a decline in net income to CN¥73.33 million for the nine months ended September 2025, compared to CN¥599.22 million a year ago.

In light of our recent growth report, it seems possible that Suning.com's financial performance will exceed current levels. Dive into the specifics of Suning.com here with our thorough financial health report.SZSE:002024 Discounted Cash Flow as at Nov 2025

Anhui Jinhe IndustrialLtd

Overview: Anhui Jinhe Industrial Co., Ltd. is involved in the R&D, production, and sales of food additives, daily chemical flavors, bulk chemicals, and intermediates with a market cap of CN¥11.86 billion.

Operations: The company generates revenue through its involvement in the research, development, production, and sales of food additives, daily chemical flavors, bulk chemicals, and intermediates.

Estimated Discount To Fair Value: 34.4%

Anhui Jinhe Industrial Ltd. is trading at CN¥22.41, significantly below its estimated fair value of CN¥34.17, suggesting potential undervaluation based on cash flows. The company's earnings are forecast to grow substantially at 40.6% annually over the next three years, outpacing the broader Chinese market growth rate of 27.4%. However, recent results show a decline in net income to CNY 391.02 million for the nine months ended September 2025 from CNY 409.17 million a year ago.

Our growth report here indicates Anhui Jinhe IndustrialLtd may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Anhui Jinhe IndustrialLtd.SZSE:002597 Discounted Cash Flow as at Nov 2025

Where To Now?

Get an in-depth perspective on all 499 Undervalued Global Stocks Based On Cash Flows by using our screener here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:ROVI SZSE:002024 and SZSE:002597.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments